Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Company Overview

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia.

Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.

Key Stats

• Today's Range: $5.15 to $5.67
• 50-Day Range: $1.67 to $6.01
• 52-Week Range: $1.61 to $10.45
• Volume: 265,031 shs
• Average Volume: 4.81 million shs
• Market Capitalization: $8.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

QLGN Stock Analysis - Frequently Asked Questions

How have QLGN shares performed this year?

Qualigen Therapeutics' stock was trading at $4.21 on January 1st, 2025. Since then, QLGN stock has increased by 24.2% and is now trading at $5.23.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) EPS for the quarter.

When did Qualigen Therapeutics' stock split?

Qualigen Therapeutics shares reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QLGN
• CIK: 1460702
• Web: www.qualigeninc.com
• Phone: (760) 918-9165
• Fax: N/A
• Employees: 50
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -202.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $4.98 million
• Price / Sales: 1.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -1.27

Miscellaneous

• Outstanding Shares: 1,700,000
• Free Float: 1,664,000
• Market Cap: $8.89 million
• Optionable: Not Optionable
• Beta: 0.32